Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any congenital myasthenic syndrome in which the cause of the disease is a mutation in the CHRNA1 gene.
Features include always present findings: Fatigable weakness and Upper limb muscle weakness; and common findings: Generalized muscle weakness, Hand muscle atrophy, and Diaphragmatic weakness. 20 total HPO annotations.
Data assembled from 5 of 12 sources · Last updated Oct 3, 2026, 8:13 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 9 | Type 2 muscle fiber atrophy, Fatigable weakness, Lower limb muscle weakness |
Arms and legs | 4 | Lower limb muscle weakness, Intrinsic hand muscle atrophy, Upper limb muscle weakness |
Digestive system | 2 | Difficulty swallowing (dysphagia), Feeding difficulties |
Brain and nerves | 2 | Difficulty swallowing (dysphagia), Dysarthria |
Head and neck | 1 | High palate |
Lab test results | 1 | Anti-neuromuscular Junction acetylcholine receptor antibody positivity |
Eyes | 1 | Ptosis |
Lungs and breathing | 1 | Intermittent episodes of respiratory insufficiency due to muscle weakness |
CHRNA1 encodes cholinergic receptor nicotinic alpha 1 subunit (457 aa). Upon acetylcholine binding, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane Highest expression in Muscle Skeletal (29.9 TPM) and Pituitary (1.9 TPM).
Congenital myasthenic syndrome 1A is associated with mutations in the CHRNA1 gene on chromosome 2.
The CHRNA1 protein participates in CHRNA9:CHRNA10:AcCho transports Ca2+ from the extracellular region to the cytosol pathway.
CHRNA1 is classified as a druggable target (Cell Surface, Druggable Genome, and Ion Channel categories) with score 2.5.
Genetic testing for CHRNA1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for congenital myasthenic syndrome 1A has been reported in the published literature.
Phenotype severity distribution: 2 always present features, 3 common features.
No clinical trials have been registered for congenital myasthenic syndrome 1A.
18 publications have been identified in PubMed for congenital myasthenic syndrome 1A. Research spans Case Report / Case Series (33%), Review / Meta-Analysis (22%), and Epidemiology / Natural History (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 6 | 33% |
Research summaries | 4 | 22% |
Disease patterns and progression | 3 | 17% |
Laboratory research | 2 | 11% |
Testing and diagnosis research | 1 | 6% |
Clinical study results | 1 | 6% |
New treatment approaches | 1 | 6% |
Reich C (2026). [PMID: 42113217](https://pubmed.ncbi.nlm.nih.gov/42113217/). *Clin Res Cardiol*. [Review / Meta-Analysis]
Ivanovic V (2026). [PMID: 41940306](https://pubmed.ncbi.nlm.nih.gov/41940306/). *Front Neurol*. [Case Report / Case Series]
Mascitelli JR (2026). [PMID: 42055825](https://pubmed.ncbi.nlm.nih.gov/42055825/). *J Neurointerv Surg*. [Review / Meta-Analysis]
Choe N (2025). [PMID: 40701844](https://pubmed.ncbi.nlm.nih.gov/40701844/). *The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology*. [Basic Science / Preclinical]
Zylla MM (2025). [PMID: 39115608](https://pubmed.ncbi.nlm.nih.gov/39115608/). *Clinical research in cardiology : official journal of the German Cardiac Society*. [Clinical Trial Publication]
Werr L (2025). [PMID: 39348606](https://pubmed.ncbi.nlm.nih.gov/39348606/). *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. [Epidemiology / Natural History]
Min JH (2025). [PMID: 40878311](https://pubmed.ncbi.nlm.nih.gov/40878311/). *Journal of clinical neurology (Seoul, Korea)*. [Case Report / Case Series]
Hasan AU (2025). [PMID: 41283336](https://pubmed.ncbi.nlm.nih.gov/41283336/). *Medicines (Basel, Switzerland)*. [Gene Therapy / Novel Therapeutics]
Ohno K (2025). [PMID: 40533459](https://pubmed.ncbi.nlm.nih.gov/40533459/). *Journal of human genetics*. [Case Report / Case Series]
Zhang J (2025). [PMID: 40442802](https://pubmed.ncbi.nlm.nih.gov/40442802/). *Orphanet journal of rare diseases*. [Basic Science / Preclinical]